Obinutuzumab, a Potent Anti–B-Cell Agent, for Rituximab-Unresponsive IgM Anti-Mag Neuropathy

Neurology: Neuroimmunology and NeuroInflammation - United States
doi 10.1212/nxi.0000000000000460
Full Text
Abstract

Available in full text

Categories
Neurology
Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Selective in Vivo Removal of Pathogenic Anti-Mag Autoantibodies, an Antigen-Specific Treatment Option for Anti-Mag Neuropathy

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2017English

B Cell Therapy for Rheumatoid Arthritis: The Rituximab (Anti-Cd20) Experience

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2003English

Anti-Tumor Activity of Obinutuzumab and Rituximab in a Follicular Lymphoma 3D Model

Blood Cancer Journal
OncologyHematology
2013English

Treatment With Rituximab in Patients With Polyneuropathy With Anti-Mag Antibodies

Journal of Neurology
Neurology
2011English

Artesunate Shows Potent Anti-Tumor Activity in B-Cell Lymphoma

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2018English

Biological Activities of Fusarochromanone: A Potent Anti-Cancer Agent

BMC Research Notes
BiochemistryMedicineGeneticsMolecular Biology
2014English

Anti-IgM-Mediated B Cell Signaling. Molecular Analysis of Ligand Binding Requisites for Human B Cell Clonal Expansion and Tolerance

Journal of Experimental Medicine
MedicineAllergyImmunology
1988English

Anti-HBc IgM Assays and Diagnosis of Acute Hepatitis B.

Journal of Clinical Pathology
MedicineForensic MedicinePathology
1990English

Preclinical Evaluation of Liposomal C8 Ceramide as a Potent Anti-Hepatocellular Carcinoma Agent

PLoS ONE
Multidisciplinary
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy